Notably, although monotherapy with either rhAPE1/Ref-1 or ASA did not significantly inhibit tumor growth, their combination substantially suppressed tumor growth at a rate comparable to the PTX treatment (Figure 2C). Here, APEX1 is linked to neoplasm.